Medicenna to Present at the 2023 Guggenheim Oncology Conference
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced that Dr. Fahar Merchant, President and CEO, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference on February 9, 2023, at 3:55 PM ET. This conference will showcase their innovative immunotherapy developments, including the highly selective IL-2 Superkine, MDNA11, which targets cancer-killing cells. Medicenna is also advancing its IL-4 Empowered Superkine, MDNA55, which has received FDA Fast-Track and Orphan Drug designations. Interested parties can access the webcast via the provided link and find more details on Medicenna's website.
- None.
- None.
TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference, which is scheduled to take place from February 8 – 9, 2023.
Details on the fireside chat are as follows:
2023 Guggenheim Oncology Conference | |
Date: | Thursday, February 9, 2023 |
Time: | 3:55 PM ET |
Webcast: | Link |
Webcast and replay information for this event will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.
About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna’s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
FAQ
When is Medicenna's fireside chat at the Guggenheim Oncology Conference?
Who will represent Medicenna at the Guggenheim Oncology Conference?
Where can I watch the Medicenna webcast for the Guggenheim Oncology Conference?
What is MDNA11 developed by Medicenna?